GRACEcast
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (audio)
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:08:40
- More information
Informações:
Synopsis
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
